People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CytoImmune Therapeutics, Inc. | — | Biotechnology | Series B | $36.5M | $919.9M | 2021 |
| SNIP Inc. | — | Other | Series A | $5.4M | $82.1M | 2012 |
Will Rosellini at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Will Rosellini on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard T Santulli | 1 | 1 |
| Douglas T Williams | 1 | 1 |
| Kinam T Hong | 1 | 1 |
| Aleksey Krylov | 1 | 1 |
| Mark Marmer | 1 | 1 |
| Peter Hardigan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.